Skip to main content
. 2024 Jul 9;9(7):103625. doi: 10.1016/j.esmoop.2024.103625

Figure 2.

Figure 2

Best percentage change from baseline in target lesion size based on investigator assessment.

BOR noted above or below bars for each patient. BOR, best overall response; CRC, colorectal cancer; FGF, fibroblast growth factor; FGFR, FGF receptor; GE, gastroesophageal; GI, gastrointestinal; NE, not evaluable; PD, progressive disease; pemi/doc; pemigatinib + docetaxel; pemi/gem/cis, pemigatinib + gemcitabine + cisplatin; pemi/pembro, pemigatinib + pembrolizumab; pemi/reti, pemigatinib + retifanlimab; pemi/tras, pemigatinib + trastuzumab; PR, partial response; SD, stable disease.